condep1002

condep1002 12/02/17 20:44

Ha respondido al tema Farmas USA

AMRN http://seekingalpha.com/article/4045161-amarin-secures-enough-cash-2017

Ir a respuesta

condep1002 13/01/17 15:39

Ha respondido al tema Farmas USA

http://www.fool.com/investing/2017/01/11/more-innovation-less-regulation-3-biotech-stocks-t.aspx? Trump's plan to tamp down the FDA's regulatory powers would be welcome news for this biopharma Amarin is a small-cap Irish biopharma that sells the FDA-approved omega-3 medication Vascepa, indicated for patients with severely elevated triglyceride levels. The reason this stock is worth checking out right now is because Vascepa's tremendous commercial potential has undeniably been hampered by the FDA's current regulatory guidelines. Since the drug's launch in 2013, for example, Vascepa has made respectable inroads into both the prescription omega-3 and non-statin prescription lipid therapy markets. But the drug still has a long way to go before it comes close to maxing out its commercial potential in either of these multi-billion dollar markets: Vascepa Sales Image Source: Amarin Corp. The backstory is that the FDA initially rejected the drug's supplemental new drug application, which would have included patients with only moderately high triglycerides in its list of approved uses, which slowed its commercial uptake. After a lengthy court battle, Amarin eventually won the right to talk to doctors about off-label uses for Vascepa, but the company still has to stay within the strict bounds of the drug's FDA-vetted clinical dataset. The point is that Trump's plan to turn the industry on its head from a regulatory standpoint could open the door for Amarin to market Vascepa broadly within the vast lipid therapy market, without even having to complete its ongoing cardiovascular outcomes trial. If effectiveness isn't an issue, this DNA vaccine maker is grossly undervalued Inovio Pharmaceuticals is striving to bring the first DNA-based vaccine or immunotherapy to market in the United States. The problem is that Inovio's platform, along with all other DNA vaccines to date, hasn't produced the type of clear cut effectiveness that warrants approval. To get over this hurdle, Inovio has introduced novel delivery methods, such as the Cellectra 5PSP immunotherapy delivery device, and proposed the use of immune activators in conjunction with its DNA vaccines. However, the fact remains that this biotech has yet to advance even a single product candidate into late-stage development since its inception over 16 years ago, which certainly hasn't helped the performance of its share price: INO Chart INO data by YCharts How could a Trump-directed FDA change Inovio's outlook? Inovio has completed a Phase 2 trial for its lead product candidate, VGX-3100, as a treatment for cervical dysplasia, where the vaccine produced a favorable safety profile and an intriguing efficacy signal. So while it may sound outlandish to those who have watched the FDA repeatedly reject drugs with robust clinical programs, VGX-3100 may actually be good to go based on its Phase 2 safety data under a Trump administration. The key is going to be Trump's ability to knock down the 1962 Kefauver-Harris Amendment requiring drug manufacturers to demonstrate experimental products to be both safe and effective prior to approval. After all, his administration appears keen to transition to a regulatory framework that favors "real world" evidence of a drug's effectiveness -- evidence that people like Jim O'Neill believe can be gathered after a drug is already on the market.

Ir a respuesta

condep1002 12/09/16 13:21

Ha respondido al tema Farmas USA

AMRN http://www.reuters.com/article/idUSFWN1BO01I?type=companyNews&feedType=RSS&feedName=companyNews&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+reuters%2FcompanyNews+%28News+%2F+US+%2F+Company+News%29

Ir a respuesta

condep1002 08/09/16 07:09

Ha respondido al tema Farmas USA

Here are 5 stocks that made it through this week's screen: (AMRN - Free Report) Amarin Corp. (CGEN - Free Report) Compugen (RPTP - Free Report) Raptor Pharmaceuticals (MT - Free Report) ArcelorMittal (HOV - Free Report) Hovnanian Enterprises I think each one of these picks has big potential. And the entire list is worth a thorough analysis. I would not suggest filling up an entire portfolio of stocks under $10 though. But adding a careful selection of some of the best cheap stock names could add some excess returns to your bottom line, not to mention a little excitement to your stock picking process as well. Get the rest of the stocks on this list and start screening for the best stocks under $10 for yourself. And don't forget to backtest your strategy so you'll know how successful it's been before you put any of your money at risk. You can do it. https://www.zacks.com/commentary/89923/explosive-stocks-under-10

Ir a respuesta

condep1002 22/08/16 11:51

Ha respondido al tema Farmas USA

top ten http://investorplace.com/2016/08/10-biotechnology-stocks-to-buy-now-2/

Ir a respuesta

condep1002 12/08/16 12:09

Ha respondido al tema Farmas USA

AMRN Adam Russell Adam graduated from UCL in 1998 with an honors degree in Business Finance (BSc). He has spent the last two decades identifying undervalued companies in US markets, primarily in the healthcare and insurance industries. Outside of the financial world, Fianciero specializes in undervalued companies INTERESTING IN YOUR OPINION ON AmArin; undervalued companies.

Ir a respuesta

condep1002 12/08/16 11:45

Ha respondido al tema Farmas USA

AMRN http://marketexclusive.com/whats-amarin-corporation-plc-nasdaqamrn-time/24283/

Ir a respuesta

condep1002 12/08/16 11:29

Ha respondido al tema Farmas USA

AMRN They have to have some initial data. If it wasn't good, I doubt they would keep raising money to complete reducir it.

Ir a respuesta

condep1002 11/08/16 10:11

Ha respondido al tema Farmas USA

AMRN They are going to raise enough money to complete Reduce it. The funds buying the deal are probably working for one of the large pharma companies that will acquire Amarin soon. This is a good deal if you want to get in at a low price before any takeover is announced

Ir a respuesta

condep1002 08/08/16 09:26

Ha respondido al tema Farmas USA

Benzinga's newsdesk monitors options activity to notice unusual patterns. These large volume (and often out of the money) trades were initially published intraday in Benzinga Professional . These trades were placed during Friday's regular session. ◾ International Business Machines Corp. IBM Aug16 155 Calls: 1700 @ ASK $8.25: 11k traded vs 7048 OI: $163.19 Ref ◾ Francesca's Holdings Corp FRAN Sep16 14.0 Calls: 1800 @ ASK $0.55: 1896 traded vs 16 OI: Earnings 9/14 $13.13 Ref ◾ Alibaba Group Holding Ltd BABA Oct16 90.0 Calls: 2800 @ ASK $1.97: 5948 traded vs 20k OI: Earnings 8/11 Before Open $84.89 Ref ◾ Abercrombie & Fitch Co. ANF Fri 9/2 21.0 Calls (Wkly) Sweep: 504 @ ASK $1.17: 782 traded vs 29 OI: Earnings 8/24 $20.87 Ref ◾ Bristol-Myers Squibb Co BMY Jan 2018 70.0 Calls: 4094 @ Above Ask! $4.65: 5290 traded vs 678 OI: $62.48 Ref ◾ Groupon Inc GRPN Aug16 6.0 Calls Sweep: 946 @ ASK $0.14: 1066 traded vs 383 OI: $5.67 Ref ◾ Amarin Corporation plc (ADR) AMRN Sep16 4.0 Calls Sweep: 620 @ ASK $0.22: 620 traded vs 2788 OI: $3.35 Ref

Ir a respuesta

condep1002 03/08/16 13:59

Ha respondido al tema Farmas USA

https://biotechinvesting.info/2016/08/01/amarin-amrn-and-terratech-trtc/

Ir a respuesta

condep1002 30/07/16 10:02

Ha respondido al tema Farmas USA

http://www.fool.com/investing/2016/07/12/3-risky-biotech-stocks-that-could-make-you-rich.aspx?

Ir a respuesta

condep1002 17/07/16 15:09

Ha respondido al tema Farmas USA

http://www.fool.com/investing/2016/07/12/3-risky-biotech-stocks-that-could-make-you-rich.aspx

Ir a respuesta

condep1002 02/07/16 10:20

Ha respondido al tema Farmas USA

AMRN http://www.pennystocksweekly.com/fundamental_stock_reports.php?symbol=AMARIN

Ir a respuesta

condep1002 04/06/16 18:43

Ha respondido al tema Farmas USA

http://www.pennystocksweekly.com/fundamental_stock_reports.php?symbol=AMARIN AMRN

Ir a respuesta

condep1002 01/06/16 12:43

Ha respondido al tema Farmas USA

AMRN http://www.fool.com/investing/2016/05/31/why-amarin-marketo-and-westar-energy-jumped-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2

Ir a respuesta

condep1002 01/06/16 07:06

Ha respondido al tema Farmas USA

http://www.fool.com/investing/general/2016/05/30/2-biotech-stocks-under-5-with-jaw-dropping-growth.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2

Ir a respuesta

condep1002 31/05/16 22:39

Ha respondido al tema Farmas USA

Amarin Announces FDA New Chemical Entity Market Exclusivity Determination for Vascepa(R) (icosapent ethyl) Capsules BEDMINSTER, NJ and DUBLIN, IRELAND--(Marketwired - May 31, 2016) - Amarin Corporation plc (NASDAQ: AMRN) announced today that the U.S. Food and Drug Administration (FDA) has determined that Vascepa® (icosapent ethyl) capsules are eligible for five-year, new chemical entity (NCE), marketing exclusivity pursuant to the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act. This determination provides Vascepa with the benefits of NCE exclusivity afforded by statute. NCE exclusivity for Vascepa runs from its date of FDA approval on July 26, 2012 and extends until July 26, 2017. The statutory 30-month stay triggered by patent litigation following generic application submissions permitted on July 26, 2016 would expire on January 26, 2020, seven-and-a-half years from FDA approval. "Amarin's goal is to protect the commercial potential of Vascepa to 2030," stated John F. Thero, president and chief executive officer of Amarin. "NCE regulatory exclusivity complements multiple patents covering Vascepa with expiration dates in 2030."

Ir a respuesta

condep1002 25/05/16 07:11

Ha respondido al tema Farmas USA

http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-novavax-inc-may-24-2016/

Ir a respuesta

condep1002 24/05/16 20:44

Ha respondido al tema Farmas USA

http://247wallst.com/healthcare-business/2016/05/23/10-speculative-biotech-and-biohealth-stocks-with-massive-analyst-upside-calls/ Amarin Amarin Corp. (NASDAQ: AMRN) was assumed with a Buy rating and a $3.50 price target (versus a $1.57 prior close) at Jefferies on May 12. The firm said it believes that the off-label Vascepa promotion in mixed dyslipidemia may be starting to bear fruit. It said: We believe off-label Vascepa promotion in mixed dyslipidemia may be beginning to bear fruit, where our analysis of TRx data suggests a steeper upward trend in recent months v. 2015. Access to this population is a major source of upside, where we see opportunity of $2.5 billion. Focus is also on REDUCE-IT where we believe Vascepa can show a benefit on final analysis in early 2018, and upside could be $14 per share. Read more: 10 Speculative Biotech and Biohealth Stocks With Massive Analyst Upside Calls - Amarin Corp plc (ADR) (NASDAQ:AMRN) - 24/7 Wall St. http://247wallst.com/healthcare-business/2016/05/23/10-speculative-biotech-and-biohealth-stocks-with-massive-analyst-upside-calls/#ixzz49bHOVIGF Follow us: @247wallst on Twitter | 247wallst on Facebook

Ir a respuesta

condep1002 10/05/16 11:57

Ha respondido al tema Farmas USA

Como del 06 de de mayo de , 2016, prevé que el consenso entre los analistas de inversión 9 encuestados que cubren Amarin Corporation plc ( ADR ) informa que la empresa va a superar el mercado. Esto ha sido el consenso pronosticado desde el sentimiento de los analistas de inversiones mejoró el 19 de febrero de 2015. La previsión de consenso anterior aconseja a los inversores mantener su posición en Amarin Corporation plc http://markets.ft.com/research/Markets/Tearsheets/Forecasts?s=AMRN:NMQ

Ir a respuesta

condep1002 10/05/16 10:54

Ha respondido al tema Farmas USA

http://www.smarteranalyst.com/2016/05/06/h-c-wainwright-reiterates-buy-amarin-corporation-plc-adr-following-1q16-update/ http://www.marketbeat.com/stocks/NASDAQ/AMRN/ 5/9/2016 HC Wainwright Reiterated Rating Buy $10.00

Ir a respuesta

condep1002 25/01/16 19:19

Ha respondido al tema Farmas USA

First, JELIS (53% RRR in the closest group to RI), CHERRY (plaque decrease) and multiple other studies that show incredible benefit of EPA. ZU posts new studies nearly daily that show multiple benefits. In order for RI to fail, all these must be false. That is impossible because they aren't related to each other. Trust me, I read more on EPA than I ever wanted to know about any drug. So based on this, I am convinced that V will decrease the rate of CVD. Let's get more specific. I was fortunate that a very informative investor shared with me his calculations of multiple scenarios that could occur. Although his calculations are incredibly thorough, I realize it's not guaranteed to be 100% accurate because we don't have all the information, but this is the best there is, with the information that was made available publicly. Using enrollment numbers, he created a matrix (it's not simple math): x axis - placebo rates, y axis RRR, inside the matrix are dates of when 967 and 1612 will occur. Again, this is based on enrollment numbers, placebo rate and RRR. So for example, this matrix shows that if placebo rate is 5.2 and RRR is 30%, #967 will occur on February xx.Important to remember, because we don't know the placebo rate, we can't use this to predict anything but we can use it to give is different possibilities, such as the example I just gave or if placebo rate is 5.6 and RRR is 40%, 967 will occur in February xx or if placebo rate is 4.9 and RRR is 8%, 967 occurred in November. So there are many many possibilities but they can be easily narrowed down. The company said that interim must occur in 2016 and final in 2017. With this rule in mind, intrerim must occur in January-February, with a slight chance for early March as well. Anything after that will not give enough for the remaining 645 events to occur.

Ir a respuesta

condep1002 28/12/15 16:39

Ha respondido al tema Farmas USA

Goldman & Company boosted its stake in shares of Amarin Co. plc (NASDAQ:AMRN) by 321.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The hedge fund owned 1,282,306 shares of the biopharmaceutical company’s stock after buying an additional 977,861 shares during the period. J. Goldman & Company’s holdings in Amarin Co. plc were worth $2,475,000 at the end of the most recent quarter

Ir a respuesta

condep1002 26/12/15 13:48

Ha respondido al tema Abengoa levanta el vuelo

No os preocupéis esta mañana me ha dicho que se prepara la GRAN COALICIÓN; PESOEMOS = PSOE+PODEMOS+IZQUIERDA UNDIDA+ E APOYO PUNTUAL DE NACIONALISTAS SECIONISTAS; y una de las condiciones que ha puesto SUSANA ES SALVAR A ABENGOA; esto se parece a la película "Salvar al soldado Rayan" ya ha muerto 3/4 partes de la empresa vamos a salvar la que queda para que la jerarquía andaluza permanezca; PARA GARANTIZARSE EL APOYO ANDALUZ, Aquí cada uno tendrá su parte ; creedme, cada uno sacara lo suyo , y adivináis de donde va a salir la pasta si....si... lo adivinasteis del bolsillo de los contribuyentes . Luego dentro de unos cuantos años ya veremos; alguno vendrá que tendrá que arreglarlo digo yo; si el barco llamado España no se hunde.

Ir a respuesta